返回
公司介紹
董事會
管理團(tuán)隊(duì)
合作伙伴
企業(yè)榮譽(yù)
專利布局
納基奧侖賽
認(rèn)證醫(yī)療機(jī)構(gòu)名單
創(chuàng)新支付
研發(fā)管線
學(xué)術(shù)發(fā)表
公司新聞
產(chǎn)品新聞
媒體報(bào)道
企業(yè)文化
招賢納士
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
Inaticabtagene Autoleucel (CNCT19) in Relapsed and Refractory B-cell Lymphoma: Results of a Phase I Clinical Trial
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory Large B-cell Lymphoma
Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
Long-Term Activity of combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial
010-65960020
pr@juventas.cn
查看更多 +